Owen Mumford announced today that it appointed Bal Johal as its director of research and development, effective next month.
Johal will become the director of R&D for the Woodstock, United Kingdom-based developer of medical devices, including the Aidaptus auto-injector, on July 4, 2022.
She has most recently served as VP of product development, quality, regulatory and medical with Circassia. Before that position, she held roles within R&D at GlaxoSmithKline, Pfizer and Mudipharma Research, according to a news release.
“To join Owen Mumford at this time is very exciting,” Johal said in the release. “With a combination of progress already made and some very talented people within the organization, I can see that we will be able to deliver a high standard of success and innovation that will have a truly positive impact.”
Owen Mumford said R&D remains at the heart of its efforts, representing a “major pillar” in the company’s strategic direction and development.
The company feels the appointment of Johal into the role heading up R&D will enhance the quality and strength of its existing pipeline of products while also securing a “well-defined path” to offer new ambitions in innovation, sustainable product design, life-cycle analysis and increased positive impact on healthcare professionals and patient experience.
“We welcome Bal very warmly into our business,” Owen Mumford Managing Director Jarl Severn said. “She has the background, experience and drive to continue to accelerate the innovation and forward-thinking that will see us achieve ambitious growth and set us apart from the competition.”
